Login
$AKTS
$16.16 -$0.46 (2.77%) Live

$AKTS SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors

24 Sep 2026 Form 4: Czibere Akos, Chief Medical Officer

Received 12,500 shares by exercise or conversion ($61.9K) · Sold 12,500 shares ($259K)

23 Sep 2026 144
13 Aug 2026 10-Q
13 Aug 2026 8-K: Results of Operations and Financial Condition

Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumors

21 Jul 2026 Form 4: Herrmann Ken, Director

Received 4,856 shares by exercise or conversion ($2.86K) · Sold 4,856 shares ($119K)

20 Jul 2026 Form 4: Herrmann Ken, Director

Received 3,065 shares by exercise or conversion ($245) · Sold 3,065 shares ($77.3K)

20 Jul 2026 144
17 Jul 2026 144
10 Jul 2026 Form 4: Ron-Bigger Shulamit, Chief Operating Officer

Received 50,000 shares by exercise or conversion ($183K) · Sold 50,000 shares ($1.39M)

10 Jul 2026 Form 4: Czibere Akos, Chief Medical Officer

Received 50,000 shares by exercise or conversion ($248K) · Sold 50,000 shares ($1.39M)

08 Jul 2026 144
08 Jul 2026 144
14 May 2026 SCHEDULE 13G
11 May 2026 10-Q
11 May 2026 8-K: Results of Operations and Financial Condition

Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments

16 Apr 2026 Form 4: Gormley Glenn, Director

Granted 37,866 Stock Option (Right to Buy)

16 Apr 2026 Form 3: Gormley Glenn, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support